NASDAQ Debut Surges Over 30% in Six Days… Betting on Undruggable Cancer Targets

Parabilis Medicines Inc. (Nasdaq: PBLS) closed at $26.59 on the Nasdaq on the 16th, up 6.32%. Trading volume topped 3.01 million shares, and the company’s market capitalization reached approximately $3.1 billion (about KRW 4.3 trillion), reflecting a one-day gain of roughly $210 million (KRW 290 billion).

In its IPO last week—priced at $20 per share—Parabilis raised around $670 million. Regeneron’s $75 million investment brought total proceeds to $745 million (about KRW 1.0 trillion). The two companies also forged a strategic alliance to co-develop antibody–Helicon conjugate therapies based on Parabilis’s Helicon platform. In March, Parabilis reported early clinical data in patients with familial adenomatous polyposis (FAP), showing that its lead candidate, zolucatetide, significantly reduced both polyps and tumors, further validating its platform.

Headquartered in Cambridge, Massachusetts, Parabilis is a clinical-stage biopharmaceutical company developing cancer treatments that target proteins long considered “undruggable,” using stabilized alpha-helical peptides called Helicons. Its pipeline centers on zolucatetide, which directly blocks the β-catenin/TCF protein interaction, and includes targeted degraders for ERG and ARON in prostate cancer. With no commercial revenue to date, the company remains in a high-risk, early-growth phase—an important consideration for prospective investors.